Kezar Life Sciences Announces IDMC Safety Review Of PORTOLA Trial Of Zetomipzomib In Patients With Autoimmune Hepatitis; Announces PALIZADE Phase 2b Clinical Trial In Patients With Active Lupus Nephritis Will Be Discontinued; Focusing Resources On Clinical Development Of Zetomipzomib In AIH
Portfolio Pulse from Benzinga Newsdesk
Kezar Life Sciences announced that the PORTOLA trial of zetomipzomib for autoimmune hepatitis will continue without changes, while the PALIZADE trial for lupus nephritis will be discontinued due to safety concerns. The company will focus on developing zetomipzomib for autoimmune hepatitis.
October 17, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Kezar Life Sciences is discontinuing its PALIZADE trial for lupus nephritis due to safety concerns and will focus on the PORTOLA trial for autoimmune hepatitis, which continues without issues.
The discontinuation of the PALIZADE trial due to safety concerns is a negative development, likely impacting investor sentiment negatively. However, the continuation of the PORTOLA trial without issues provides some positive outlook. Overall, the immediate impact is likely negative due to the safety concerns and trial discontinuation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100